protocadherin related 15Genealiases: CDHR15 · DFNB23 · USH1F
Q-omics provides the consensus-scored PCDH15 profile across patient tissues and cancer cell-line models. PCDH15 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, PCDH15 is differentially expressed in 11, with the highest sampling consensus in LUAD. Additionally, PCDH15 RNA expression shows 12,943 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BLCA, LUAD, and THYM as cancer lineages where PCDH15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PCDH15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PCDH15 survival associations across molecular data types. PCDH15 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PCDH15 RNA expression–survival associations across cancer types. High PCDH15 expression shows unfavorable associations in BLCA, UCEC, UVM and MESO, but favorable associations in PAAD and LGG. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for PCDH15 RNA expression.
This table summarizes PCDH15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for PCDH15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PCDH15 shows lower tumor expression in LUAD, KIRC, LUSC, KIRP, COAD and KICH. The LUAD box plot shows higher PCDH15 RNA expression in normal versus tumor tissue (log2 FC = −0.983, t-test p < 0.001).
This table shows molecular features associated with PCDH15 in patient tissues and cancer cell lines. In patient samples, PCDH15 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, PCDH15 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Lymphoma.
